A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)

This study is for women with advanced ovarian cancer, fallopian tube cancer, or primary peritoneal cancer that has come back after previous treatment with platinum-based chemotherapy. It tests whether combining two drugs — CAELYX (liposomal doxorubicin, already used for ovarian cancer) and YONDELIS (trabectedin, the study drug) — works better than CAELYX alone at slowing down the cancer's progression. You may be eligible if: - You are female and 18 years of age or older - You have epithelial ovarian, fallopian tube, or primary peritoneal cancer confirmed by a tissue or cell sample - You have previously received only one platinum-based chemotherapy regimen - Your cancer came back or got worse at least 6 months after starting that treatment (or after completing 6 full treatment cycles) - Your cancer can be measured on a scan You may NOT be eligible if: - You have received more than one prior chemotherapy regimen - Your cancer got worse within 6 months of starting platinum chemotherapy - Your CA125 level is rising but there is no scan evidence of the cancer progressing Talk to your doctor about whether this trial might be right for you.